Ti-Tre contains liothyronine sodium (t3), one of four natural thyroid hormones. This helps combat problems closely linked to a diminishing thyroid gland – an inevitable part of the ageing process – and our crucial metabolic functions, which are key to energy levels and all-round health.
The Ti-Tre supplement also helps address the underactive thyroid condition known as hypothyroidism, which can lead to numerous health problems. Weight gain, fatigue, muscular weakness and poor concentration levels can all be caused by an underactive thyroid. Ti-Tre is therefore instrumental in maintaining the youthful vigour that we all crave in later life.
Ti-Tre is safe, easy and effective. Side effects are rare and easily monitored, and dosage is typically 1-3 Ti-Tre tablets taken orally each day.
One tablet contains: Main ingredient: 20 mcg sodium liothyronine (Thyroid T3)
Sodium chloride, corn starch, gum Arabic, magnesium stearage, lactose.
TI-TRE IS RECOMMENDED FOR:
Hypersensitivity to the ingredients, thyrotoxicosis, uncompensated cardiac insufficiency.
See WARNING. Thyroid preparations do not easily enter the placenta. Moreover, clinical experience shows no side effects on the foetus from the administration of thyroid preparations to the mother during pregnancy. If hypothyroidism is diagnosed during pregnancy, the expectant mother must undergo treatment with thyroid preparations. Treatment must not be interrupted during pregnancy, but rather continued under a doctor's supervision. Even though only a small amount of thyroid hormones are excreted into mother's milk, thyroid preparations should be taken with caution by nursing mothers.
Liothyronine may cause increased action by the vitamin K and a mutual increase of tricyclic antidepressants. Taking liothyronine requires an adjustment in the dosage of hypoglycemia treatment. Colestiramina and probably barbiturates and ethionamide reduce the action of thyroid hormones. Diphenylidantoin by injection.
This product is to be taken with caution and only under a doctor's supervision by patients with myocardial infarction, angina pectoris, myocarditis, cardiac insufficiency with tachycardia, arterial hypertension.
Patients in this category taking sympathomimetic amines should be monitored. Patients with coronaropathy who are treated with thyroid hormones are to be closely observed during surgery as the likelihood of cardiac arrhythmia can be greater.
At the beginning of TI-TRE treatment, both diabetics taking either insulin or medicine for hypoglycemia by mouth and patients taking anticoagulant products should undergo laboratory tests to prevent phenomena of alteration and also adapt to a new daily dosage.
Since rare cases have been seen of hepatic dysfunction in connection with thyroid preparations, the patient is recommended to lower the dosage or even stop treatment if he should experience fever or weak muscles, or if the results of laboratory tests for hepatic functioning should so indicate.
Diphenylidantoin must not be injected during TI-TRE treatment. Patients with panipopituitarism or other problems related to surrenal insufficiency may react unfavorably to thyroxine; patients are thus advised to initiate a corticosteroid based treatment before taking TI-TRE.
The use of pharmaceutical products with thyroid hormones for treating obesity is dangerous since, in certain doses, they can provoke considerable secondary effects.
DOSAGE AND DIRECTIONS FOR USE:
With myxoedema, when an immediate effect is not required, it is preferable to start treatment with small doses (10-20 mcg), gradually increasing over a few days until reaching 80-100 mcg. Although this dosage is normally sufficient for maintenance treatment, it is advisable that thyroxine be taken for continued treatment.
The drawbacks of this substance in the treatment of hypometabolical symptoms in fact become advantages in a lifetime treatment.
In myxoedema resistant to the thyroid extract and to thyroxine, triidothyronine is irreplaceable. The daily dosage of TI-TRE should be divided into two or three doses.
The initial dose for children and elderly patients is 5 mcg daily, gradually increasing according to the patient's response.
In patients with myxoedema complicated by cardiac lesions, too rapid a regularization of the metabolic situation may lead to serious complications. A rigorous graduation of the dosage is essential in such cases.
IN CASE OF OVERDOSE:
Acute overdose generally produces the same symptoms as those of hypothyroidism. Should these be detected, the correct symptomatic support therapy should be introduced. Treatment consists mainly of reducing gastro-intestinal absorption (inducing vomiting, gastric lavage) and in contrasting central and peripheral effects, especially those due to the increase in sympathetic activity (administration of digitalis if cardiac insufficiency is shown, of beta blockers to control sympathetic hyperactivity, adoption of correct measures to control fever, hypoglycemia and loss of fluids).
Occasionally and especially at the beginning of treatment, or in cases of hyperdose, the following side effects will be experienced: anginous pain, cardiac arrhythmia, increased blood pressure, palpitations, cramps in the skeletal muscles, trembling.
Tachycardia, diarrhea, insomnia, excitability, headaches, fever, hot flushes, menstrual irregularities, excessive perspiration, weight loss and weak muscles are other possible side effects.
Should these take place, the patient is advised, under medical supervision, to lower the daily dosage or interrupt treatment for a few days. The patient should inform his doctor or chemist of any side effect not described in this leaflet.
Do not use this product after the expiry date given on the box.
The above information is the translation of the manufacturer's insert. It is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.